Peppy research library
Find the name.
Read the full context.
Browse Peppy’s source-aware compound library in full. Search by a familiar name or alias, compare evidence labels, and open every reference behind an entry.
Browse A–Z
The compound library
Showing published entries from Peppy’s catalogue. Collection updated 2026-10-08.
79 entries
Abaloparatide
Hormonal and Signaling
Abaloparatide is a synthetic analogue of parathyroid-hormone-related protein used in specific osteoporosis indications. Its regulated clinical evidence does not make it a general-purpose tissue-repair or performance compound.
This is a source-backed medicine and safety summary, not a recommendation or a protocol. Product labels, approvals, contraindications, interactions and availability differ by jurisdiction; check the current official product information and consult a qualified clinician.
ACE-031
Hormonal and Signaling
ACE-031 is an investigational soluble activin type IIB receptor-Fc fusion protein designed to trap myostatin and related ligands. Its Duchenne muscular dystrophy programme was stopped for vascular adverse effects, and it has never been approved.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
Amycretin
Metabolic
Amycretin is an investigational single molecule that activates both GLP-1 and amylin receptors. Early randomised trials have studied oral and once-weekly subcutaneous formulations in overweight or obesity; neither formulation is approved.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
AOD-9604
Metabolic
AOD-9604 is a modified human-growth-hormone fragment. FDA's 2024 review describes limited clinical-study summaries and reports that a 502-person obesity trial did not show a significant primary-endpoint difference from placebo.
FDA notes incomplete study reporting, no FDA-approved AOD-9604 products, and insufficient evidence for obesity treatment. This does not support use for any other goal, route, formulation, protocol, or dose.
ARA-290
Tissue Repair and Healing
ARA-290 (cibinetide) is an 11-amino-acid erythropoietin-derived peptide that activates tissue repair without stimulating red-cell production. It has completed human trials in small-fibre neuropathy but is not approved.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
Argireline
Cosmetic and Skincare
Argireline is a topical cosmetic hexapeptide marketed as a needle-free alternative to botulinum toxin. Its skin penetration is the weak point: over 99% of an applied dose does not reach the dermis.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
BPC-157
Tissue Repair and Healing
BPC-157 is a synthetic pentadecapeptide being investigated in preclinical and very small human studies. A 2024 single-site pilot report in 12 participants is available, but it does not establish effectiveness or general safety.
Human evidence is sparse, uncontrolled, and not sufficient to establish safety or effectiveness. This record is not an approval, a protocol, or a recommendation; product quality and regulatory status require independent verification.
Cagrilintide
Metabolic
Cagrilintide is a long-acting amylin analogue studied in randomised weight-management trials. A phase 2 dose-finding trial reported greater mean weight reduction than placebo in its selected study population.
Trial findings are population-, formulation-, and protocol-specific. This is not a prescribing or combination recommendation; current regulatory status and product labelling must be checked locally.
CagriSema
Multi peptide
CagriSema is a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg given once weekly. Unlike the other blends in this category it has been through phase 3 and published in the New England Journal of Medicine; it is not yet approved.
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
Cerebrolysin
Neuropeptides
Cerebrolysin is a preparation of low-molecular-weight peptides and amino acids. Randomised controlled studies have examined it in selected neurological conditions, including acute stroke and cognitive disorders.
Study results are indication-specific and mixed across outcomes and trials. This summary does not establish approval, safety for an individual, or a treatment recommendation.
CJC-1295 (without DAC)
Hormonal and Signaling
CJC-1295 without DAC is kept separate from long-acting DAC-containing formulations. A clinical review identifies CJC-1295 among unapproved peptide therapies but provides no formulation-specific primary evidence for this non-DAC record.
The source does not establish the identity, pharmacokinetics, clinical benefit, or safety of a no-DAC formulation. Do not transfer findings or half-life estimates from DAC-containing CJC-1295.
CJC-1295 / GHRP-2 blend
Multi peptide
A research-market blend generally pairing Modified GRF 1-29, sold as “CJC-1295 without DAC,” with GHRP-2. FDA documents the multi-ingredient powder, but names, chemical forms and ratios vary and no approved formulation exists.
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
CJC-1295 / GHRP-6 blend
Multi peptide
A research-market blend generally pairing Modified GRF 1-29, sold as “CJC-1295 without DAC,” with GHRP-6. FDA documents products under this component formula, but there is no standard ratio or approved combination.
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
CJC-1295 / Hexarelin blend
Multi peptide
A research-market blend generally pairing Modified GRF 1-29, sold as “CJC-1295 without DAC,” with hexarelin. FDA documents the marketed multi-ingredient powder; no standard ratio, approved formulation or combination trial exists.
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
CJC-1295 / Ipamorelin blend
Multi peptide
A co-lyophilised vial pairing CJC-1295 without DAC (Modified GRF 1-29) with Ipamorelin at a fixed 1:1 ratio by mass, sold as 5 mg/5 mg or 10 mg/10 mg. It is the most common growth-hormone blend, and its ratio is a manufacturing convention rather than a studied one.
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
CJC-1295 with DAC
Hormonal and Signaling
CJC-1295 is a long-acting growth-hormone-releasing hormone analogue. A small randomised, placebo-controlled study in healthy adults reported sustained increases in growth hormone and IGF-1 after administration of the study formulation.
This biomarker study does not establish clinical benefit or long-term safety. It should not be applied to products with a different formulation or used as dosing guidance.
CJC-1295 with DAC / Ipamorelin blend
Multi peptide
A research-market blend pairing long-acting CJC-1295 with DAC and short-acting ipamorelin, sometimes branded Hulk Stack or Hulk Blend. The nickname and ratio are not standardised, and this is a different formulation from the existing non-DAC CJC/Ipamorelin blend.
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
Dulaglutide
Metabolic
Dulaglutide is a once-weekly GLP-1 receptor agonist approved as Trulicity for type 2 diabetes and for cardiovascular risk reduction in that population. It is not approved for weight management.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
Epitalon
Hormonal and Signaling
Epitalon is a synthetic tetrapeptide. Recent published work located for this review is cell-line research examining telomere-related measures, rather than human clinical treatment evidence.
Cell-line findings cannot establish human benefit or safety, including for ageing-related outcomes. No clinical protocol, dose, or long-term safety conclusion is provided.
Exenatide
Metabolic
Exenatide was the first GLP-1 receptor agonist approved for type 2 diabetes, marketed as twice-daily Byetta and weekly extended-release Bydureon. It is not approved for weight management.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
GHK-Cu
Cosmetic and Skincare
GHK-Cu is the copper complex of the naturally occurring tripeptide GHK. A small randomized study evaluated a topical GHK-Cu-containing skincare regimen after laser resurfacing; it did not show objective improvement in the main assessed skin outcomes.
This is limited topical, product-specific human evidence. It does not establish effectiveness or safety for other routes, preparations, goals, or long-term use. This record is not a treatment or preparation recommendation.
GHRP-2
Hormonal and Signaling
GHRP-2 is a synthetic growth-hormone-releasing peptide. Small human physiology studies reported acute growth-hormone responses and also measured prolactin, ACTH, and cortisol responses.
Small, short-term endocrine studies do not establish clinical benefit or long-term safety. No dosing or protocol recommendation is provided.
GHRP-6
Hormonal and Signaling
GHRP-6 is a synthetic growth-hormone-releasing peptide. A small pharmacokinetic study in healthy male volunteers measured its disposition after a single intravenous administration.
This is a small pharmacokinetic study and not evidence of benefit or long-term safety. It does not support a schedule or dose recommendation.
Glepaglutide
Metabolic
Glepaglutide is an investigational long-acting GLP-2 analogue for short bowel syndrome with intestinal failure. A positive phase 3 trial has been published, but the compound is not an approved medicine.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
GLOW
Multi peptide
GLOW is a vendor-assembled three-peptide blend, most commonly sold as a 70 mg vial of GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg. Totals and ratios differ between suppliers; it is KLOW without the KPV.
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
Gonadorelin
Hormonal and Signaling
Gonadorelin is synthetic gonadotropin-releasing hormone, formerly approved as Factrel for diagnostic pituitary testing. No FDA-approved product is currently marketed in the United States.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
Hexarelin
Hormonal and Signaling
Hexarelin is a synthetic growth-hormone-releasing peptide. Small human physiology studies reported acute changes in growth hormone and other measured endocrine markers.
These small, short-term studies do not establish clinical benefit or long-term safety. Peppy does not infer safety from hormone-response data.
Humanin
Metabolic
Humanin is a mitochondrial-derived peptide. Human studies cited here measure endogenous circulating levels in response to physiological or disease contexts; they do not establish a therapeutic use for administered Humanin.
Observational biomarker findings do not demonstrate benefit or safety of supplementation. No dose, protocol, or interaction conclusion is provided.
IGF-1 DES
Hormonal and Signaling
IGF-1 DES (Des1-3 IGF-I) is a modified IGF-1 analogue. An analytical study includes it among synthetic analogues measured in plasma; it does not establish clinical benefit or safety for a marketed preparation.
The source is analytical and preclinical, not a formulation-specific clinical profile. Do not treat this analogue as interchangeable with licensed recombinant human IGF-1 medicines or endogenous IGF-1.
IGF-1 LR3
Hormonal and Signaling
IGF-1 LR3 (LongR3-IGF-I) is a modified IGF-1 analogue. An analytical study describes detection and metabolite work, including rodent experiments; it is not a clinical efficacy study.
The source is analytical and preclinical, not a formulation-specific clinical profile. Do not treat this analogue as interchangeable with licensed recombinant human IGF-1 medicines or endogenous IGF-1.
Insulin icodec
Metabolic
Insulin icodec is an ultra-long-acting basal insulin analogue authorised as Awiqli in Europe for adults with diabetes. Reversible albumin binding extends its action sufficiently for once-weekly administration; it is also the insulin component of Kyinsu/IcoSema.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
Ipamorelin
Hormonal and Signaling
Ipamorelin is included in the growth-hormone-releasing peptide family in a human analytical study. Peppy has not curated an efficacy or clinical-safety profile from primary clinical trials.
Detection or analytical research does not demonstrate benefit or safety. No dosing, protocol, or interaction conclusion is provided.
Kisspeptin-10
Hormonal and Signaling
Kisspeptin-10 is the decapeptide fragment of kisspeptin that activates KISS1R to trigger GnRH release. It has been studied in humans as a reproductive-axis probe and potential IVF trigger, but is not approved anywhere.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
KLOW
Multi peptide
KLOW is a vendor-assembled four-peptide blend sold as a single 80 mg lyophilised vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. It is not a licensed product and has no literature of its own.
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
KPV
Tissue Repair and Healing
KPV (Lys-Pro-Val) is a tripeptide studied in cell systems and mouse colitis models, where the cited work examined transporter-mediated uptake and inflammatory signalling.
The cited work is preclinical and does not establish clinical efficacy, safety, interactions, half-life, protocol, or dosing for a marketed KPV product.
Kyinsu
Multi peptide
Kyinsu is the European-authorised name for IcoSema, a once-weekly fixed-ratio pre-filled pen combining insulin icodec and semaglutide for selected adults with insufficiently controlled type 2 diabetes. It is a regulated combination medicine, unlike the research-market blends in this category.
This is a source-backed summary of the authorised Kyinsu fixed-ratio medicine, not a recommendation or a guide to switching insulin. The evidence and regulatory status belong to the manufactured pre-filled pen; separately sourced or co-mixed insulin icodec and semaglutide are not equivalent. Insulin errors can cause prolonged severe hypoglycaemia and require clinician-directed prescribing and monitoring.
Larazotide acetate
Tissue Repair and Healing
Larazotide is an oral tight-junction regulator developed for coeliac disease. Its phase 3 trial was stopped at interim analysis in 2022, so no confirmatory efficacy evidence exists.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
Linaclotide
Hormonal and Signaling
Linaclotide is a 14-amino-acid guanylate-cyclase-C agonist with approved gastrointestinal indications. It acts mainly on the luminal surface of the intestinal epithelium and has negligible systemic availability at labelled oral doses.
This is a source-backed medicine and safety summary, not a recommendation or a protocol. Product labels, approvals, contraindications, interactions and availability differ by jurisdiction; check the current official product information and consult a qualified clinician.
Liraglutide
Metabolic
Liraglutide is a once-daily GLP-1 receptor agonist. It is FDA-approved as Victoza for type 2 diabetes and as Saxenda for chronic weight management, with separate labelling and dose ranges for each.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
Lixisenatide
Metabolic
Lixisenatide is a short-acting, once-daily GLP-1 receptor agonist approved as Adlyxin for glycaemic control in adults with type 2 diabetes. It is not approved for weight management.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
LL-37
Antimicrobial
LL-37 is an endogenous human cathelicidin peptide. Controlled clinical studies have examined topical LL-37 in hard-to-heal venous leg ulcers; a multicentre phase IIb trial did not find a significant difference in the full study population, with a post-hoc subgroup observation requiring further study.
This clinical research is topical and wound-specific. It does not establish effectiveness or safety for other routes, preparations, conditions, or self-directed use. No protocol or dosing guidance is provided.
Mazdutide
Metabolic
Mazdutide is a dual GLP-1 and glucagon receptor agonist studied in randomised phase 2 trials in Chinese adults with type 2 diabetes or overweight/obesity.
The cited studies are time-limited and population-specific. They do not establish universal benefit, long-term safety, or an individual treatment plan.
Mecasermin
Hormonal and Signaling
Mecasermin is recombinant human IGF-1 approved as Increlex for narrowly defined severe primary IGF-1 deficiency in children. It is the approved, sequence-native reference point for the unapproved IGF-1 LR3 and IGF-1 DES analogues.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
Melanotan II
Cosmetic and Skincare
Melanotan II is a synthetic melanocortin analogue. A very small, early phase-I study in three volunteers documented melanotropic effects and adverse effects; this is not a modern efficacy or broad safety evidence base.
A three-person exploratory study does not establish effectiveness or safety. It must not be used to infer a suitable dose, product quality, long-term outcomes, or use for any purpose. Peppy provides no protocol or dosing guidance.
Melanotan-1 (MT-1)
Cosmetic and Skincare
Melanotan-1 (MT-1), now known pharmaceutically as afamelanotide, is an MC1R agonist. The approved Scenesse formulation is a 16 mg subcutaneous implant used to increase pain-free light exposure in adults with erythropoietic protoporphyria; that approval does not establish unregulated injectable products as equivalent.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
MGF
Hormonal and Signaling
Mechano-growth factor (MGF) refers to an IGF-1 splice-variant concept. Human exercise studies measure MGF-related mRNA expression, while synthetic MGF-peptide findings are principally cell and animal research; one independent in-vitro replication study found no apparent effect on human or mouse myoblast proliferation or differentiation.
Endogenous transcript observations do not validate a manufactured MGF peptide as a treatment. There is no curated clinical efficacy or safety profile for the marketed peptide products represented by this record.
MK-677
Hormonal and Signaling
MK-677 (ibutamoren) is an oral growth-hormone secretagogue investigated in clinical studies. In a randomized hip-fracture trial, IGF-1 increased but most functional measures did not improve; the trial was stopped early after a congestive-heart-failure safety signal in a limited number of participants.
This single population-specific trial does not establish benefit or safety for other populations, goals, durations, formulations, or self-directed use. Peppy does not provide a protocol or dosing recommendation.
MOTS-c
Metabolic
MOTS-c is a mitochondrial-derived peptide. Foundational work reported metabolic effects in cellular and mouse models; human studies cited here measure endogenous levels rather than establishing treatment benefit.
Preclinical and biomarker observations are not evidence that administered MOTS-c is effective or safe in people. No dose, protocol, or interaction conclusion is provided.
Nandrolone decanoate
Androgens and Anabolics
Nandrolone decanoate is a depot anabolic-androgenic steroid. The available U.S. DailyMed human label describes use for anaemia of renal insufficiency, while current availability and approvals are jurisdiction-specific; that historical indication is not evidence for physique use.
“Oil” is informal gym shorthand, not a pharmacological category. This record describes the cited regulated formulation or animal-drug status only; it is not a protocol, a product-quality endorsement, or a recommendation. Human and veterinary products are not interchangeable.
Native GIP
Metabolic
Native glucose-dependent insulinotropic polypeptide (GIP) is an endogenous incretin hormone. A small randomised trial evaluated native GIP alone or with semaglutide in people with type 2 diabetes; the predefined glucose outcome was not improved.
This record is for native GIP only. It is not evidence for tirzepatide, retatrutide, other GIP/GLP-1 co-agonists, or compounded products. The trial was short and small, so it does not establish broad benefit or safety.
Oxytocin
Hormonal and Signaling
Oxytocin is a peptide hormone and prescription medicine. The current U.S. product label describes specific obstetric uses under clinical supervision; it is not a general-purpose wellness, social, or performance product.
This evidence and labelling apply to licensed medical products and specified obstetric contexts. They do not establish safety or benefit for non-prescription preparations, non-obstetric uses, or self-directed administration. Peppy does not provide dosing guidance.
Pemvidutide
Metabolic
Pemvidutide is an investigational once-weekly GLP-1/glucagon dual-receptor agonist being studied for obesity and metabolic liver disease. Human phase 2 and phase 2b results are available, but it is not approved.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
Pinealon
Neuropeptides
Pinealon (Glu-Asp-Arg; EDR) is a synthetic tripeptide. A laboratory study reported cellular effects under oxidative-stress conditions; it does not establish clinical benefit.
The cited study is cellular/preclinical. No robust formulation-specific clinical efficacy, safety, interaction, half-life, protocol, or dosing conclusion is available in Peppy.
Plecanatide
Hormonal and Signaling
Plecanatide is a uroguanylin analogue and guanylate-cyclase-C agonist with approved constipation indications. It is designed to act locally in the gastrointestinal tract and is minimally absorbed systemically at labelled oral doses.
This is a source-backed medicine and safety summary, not a recommendation or a protocol. Product labels, approvals, contraindications, interactions and availability differ by jurisdiction; check the current official product information and consult a qualified clinician.
Pramlintide
Metabolic
Pramlintide is a synthetic amylin analogue approved as Symlin for use alongside mealtime insulin in type 1 and type 2 diabetes. It is the approved reference point for the amylin mechanism that cagrilintide is built on.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
PT-141
Hormonal and Signaling
Bremelanotide is a melanocortin receptor agonist. The FDA label describes a specific approved indication for premenopausal women with acquired, generalised hypoactive sexual desire disorder; it is not labelled as a general sexual-performance treatment.
This summary reflects a U.S. product label and not an individual recommendation. Contraindications, warnings, interactions, and product availability must be checked in the current local label and with a qualified clinician.
Retatrutide
Metabolic
Retatrutide is an investigational triple agonist at GIP, GLP-1, and glucagon receptors. Randomized phase-II studies have examined it in defined type-2-diabetes and obesity populations.
Phase-II results in selected trial populations do not establish long-term safety, suitability, or approval status for an individual. This record is not a recommendation or protocol; only the studied product and context are represented by its sources.
Selank
Neuropeptides
Selank is a synthetic peptide that has been studied in a small comparative clinical report for anxiety disorders. The PubMed record is an article in Russian and does not constitute a robust, independently replicated evidence base.
The located report is limited in size, language accessibility, and applicability. It does not establish broad effectiveness, long-term safety, or suitability for other formulations, populations, or uses. Peppy provides no protocol or dosing guidance.
Semaglutide
Metabolic
Semaglutide is a GLP-1 receptor agonist marketed in different formulations and brands. Approved indications, formulations, and safety information are product- and jurisdiction-specific.
This is a label-based identity summary, not a recommendation. Check the current official label for the exact product and consult a qualified clinician before making treatment decisions.
Semax
Neuropeptides
Semax is a peptide investigated in small human neuroimaging and clinical studies. One small placebo-controlled imaging study in healthy volunteers reported short-term changes in a resting-state brain-network measure; this does not establish clinical benefit.
Available findings are narrow and do not establish efficacy, long-term safety, or a general nootropic effect. No dosing or protocol recommendation is provided.
Sermorelin
Hormonal and Signaling
Sermorelin is an analogue of growth-hormone-releasing hormone. Historical clinical literature includes diagnostic use and limited paediatric growth-hormone-deficiency treatment data; it is not evidence for general wellness or performance use.
The located evidence is condition- and population-specific, and it does not establish benefit or safety for unreviewed formulations, routes, uses, or long-term outcomes. Peppy does not provide a protocol or dosing recommendation.
Sermorelin / Ipamorelin blend
Multi peptide
A compounded or research-market pairing of sermorelin with ipamorelin. FDA has documented compounded injections containing both APIs, but there is no standard ratio, approved combination product or clinical trial of the blend.
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
Setmelanotide
Metabolic
Setmelanotide is an MC4R agonist approved as Imcivree for obesity caused by specific defects in the melanocortin pathway. Its label is narrow by design and it is explicitly not indicated for general obesity.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
Somatropin
Hormonal and Signaling
Somatropin is recombinant 191-amino-acid human growth hormone. Approved products replace deficient growth hormone in defined paediatric and adult conditions; this is the reference molecule against which secretagogues and modified growth-hormone fragments should be understood.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
SS-31
Metabolic
Elamipretide (SS-31) is a mitochondria-targeting tetrapeptide. Early randomised clinical studies have examined short-term physiological and clinical measures in selected populations.
Early or small trials do not establish broad clinical benefit or long-term safety. Findings are indication- and formulation-specific, and do not support off-label dosing guidance.
Survodutide
Metabolic
Survodutide is an investigational dual glucagon-receptor and GLP-1-receptor agonist. Randomised phase 2 studies have examined metabolic and weight-related outcomes in selected adult populations.
Investigational-trial findings do not establish general safety or suitability. This record does not recommend use, combinations, dosing, or treatment substitution.
TB-500
Tissue Repair and Healing
TB-500 is a product/marketing name used inconsistently and must not be assumed to be the same substance as full-length thymosin beta-4 or any specific fragment. A clinical review lists it among unapproved peptide therapies, but does not establish evidence for a defined TB-500 product.
The source is contextual, not a formulation-specific trial. Evidence for thymosin beta-4, fragments, or other products must not be transferred here. No protocol or dosing guidance is provided.
Teduglutide
Metabolic
Teduglutide is a GLP-2 analogue approved as Gattex for short bowel syndrome in patients dependent on parenteral support. It is the only approved GLP-2 receptor agonist.
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
Teriparatide
Hormonal and Signaling
Teriparatide is the 1-34 amino-acid active fragment of human parathyroid hormone. U.S. labels support specific osteoporosis indications in people at high fracture risk; it is not a general bone, recovery or performance product.
This is a source-backed medicine and safety summary, not a recommendation or a protocol. Product labels, approvals, contraindications, interactions and availability differ by jurisdiction; check the current official product information and consult a qualified clinician.
Tesamorelin
Hormonal and Signaling
Tesamorelin is a growth-hormone-releasing hormone analogue. U.S. Egrifta labelling describes a specific indication for reduction of excess abdominal fat in people with HIV-associated lipodystrophy; it is not labelled as general weight-loss treatment.
This is a label-based summary, not a recommendation. Formulations, indications, warnings, contraindications, and availability can differ by product and jurisdiction; check the current official label and consult a qualified clinician.
Testosterone cypionate
Androgens and Anabolics
Testosterone cypionate is an injectable depot ester of testosterone supplied as an oil solution. U.S. labelling describes replacement therapy for specific congenital or acquired testosterone-deficiency conditions; it does not establish safety or effectiveness for age-related hypogonadism alone.
“Oil” is informal gym shorthand, not a pharmacological category. This record describes the cited regulated formulation or animal-drug status only; it is not a protocol, a product-quality endorsement, or a recommendation. Human and veterinary products are not interchangeable.
Testosterone enanthate
Androgens and Anabolics
Testosterone enanthate is an injectable depot ester of testosterone. Current U.S. labelling describes prescription replacement therapy for conditions associated with deficient or absent endogenous testosterone, not a general performance or anti-ageing treatment.
“Oil” is informal gym shorthand, not a pharmacological category. This record describes the cited regulated formulation or animal-drug status only; it is not a protocol, a product-quality endorsement, or a recommendation. Human and veterinary products are not interchangeable.
Testosterone undecanoate
Androgens and Anabolics
Testosterone undecanoate is a long-acting injectable testosterone ester. The cited U.S. AVEED label limits use to adults who need testosterone replacement and for whom its benefits outweigh serious immediate injection-related risks.
“Oil” is informal gym shorthand, not a pharmacological category. This record describes the cited regulated formulation or animal-drug status only; it is not a protocol, a product-quality endorsement, or a recommendation. Human and veterinary products are not interchangeable.
Thymosin Alpha 1
Hormonal and Signaling
Thymosin alpha 1 is an immunomodulatory peptide studied in several clinical contexts. A large placebo-controlled sepsis trial did not find a clear reduction in 28-day mortality.
Results are condition-specific and do not support general immune-enhancement claims. This record does not provide an indication, dose, or treatment recommendation.
Thymosin Beta-4
Tissue Repair and Healing
Recombinant human thymosin beta-4 has been evaluated in a first-in-human phase I trial in healthy volunteers, focused on short-term safety, tolerability, pharmacokinetics, and anti-drug antibodies.
A phase I study cannot establish clinical benefit or long-term safety. Findings for recombinant study material should not be assumed to apply to other preparations.
Tirzepatide
Metabolic
Tirzepatide is a dual GIP and GLP-1 receptor agonist. U.S. labels differ by product and indication; the cited Zepbound label includes chronic weight-management and obstructive-sleep-apnoea indications for specified adults.
This is a label summary, not a recommendation. Product-specific contraindications, warnings, concomitant-medicine considerations, and country approvals must be checked against the current official label and with a qualified clinician.
Trenbolone acetate
Androgens and Anabolics
Trenbolone acetate is an anabolic steroid with FDA-approved veterinary cattle ear-implant products. It is not an FDA-approved human medicine, and evidence from cattle implants cannot establish safety, product quality or effectiveness for human use.
This entry distinguishes documented veterinary use from human use. It is not a protocol or a recommendation. Products promoted for people under this name are not made equivalent by the existence of an animal-drug approval.
VIP
Hormonal and Signaling
Vasoactive intestinal peptide (VIP) is an endogenous peptide. Small controlled human studies have examined physiological effects, including experimentally induced migraine, while an aviptadil trial in critical COVID-19 did not meet its prespecified primary endpoint.
These studies are context-specific and do not establish general benefit or safety for VIP products. They should not be interpreted as support for a protocol, preparation, or self-directed use.
Wolverine blend
Multi peptide
Wolverine is a community nickname for BPC-157 and TB-500 co-vialled in one injection rather than two. It is not a brand and has no standard ratio: suppliers sell it between 1:1 and 1:2.
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.